Key result
Upregulated miR-98, miR-222, miR-106b, and miR-197 differentiate active erythroparvovirus infection with ~90% specificity.
Why the study?
MiRNAs influence viral infection outcomes, and this study investigated their ability to selectively suppress transcriptionally active erythroparvovirus as potential antiviral therapies.
Do specific miRNAs differentiate transcriptionally active erythroparvovirus infection in patients with unexplained heart failure?
Observational (n=75)
Do specific miRNAs differentiate transcriptionally active erythroparvovirus infection in patients with unexplained heart failure?
Specific miRNAs (miR-98, miR-222, miR-106b, and miR-197) are significantly upregulated in heart failure patients with active erythroparvovirus infection, offering a potential diagnostic biomarker with >90% specificity.
May support miRNA profiling to detect active erythroparvovirus in HF biopsies; leaves open diagnostic utility pending prospective validation.
Aims MiRNAs, small non-coding RNAs, play key roles in gene regulation, cell differentiation, and tissue development. They influence viral infection outcomes by directly interacting with viral genomes or modifying the host microenvironment. This study demonstrates miRNAs' ability to selectively suppress transcriptionally active erythroparvovirus, highlighting their potential in antiviral therapies. Methods Seventy-five endomyocardial biopsy (EMB) specimens from patients with unexplained heart failure were analyzed. The samples included 19 with dilated cardiomyopathy and inflammation (DCMi), 12 with dilated cardiomyopathy (DCM), 25 with inflammation and active erythroparvovirus infection, 13 with active erythroparvovirus infection only, and 6 from undiagnosed patients as controls. miRNA expression was measured using TaqMan assays. Results MiR-98, miR-222, miR-106b, and miR-197 were significantly upregulated in patients with transcriptionally active erythroparvovirus infection, independent of inflammation (P < 0.005). These miRNAs differentiated these patients from all other groups with over 90% specificity. Conclusions These specific miRNAs offer a novel diagnostic tool for active erythroparvovirus infections and hold promise as therapeutic targets, providing safer alternatives to traditional antiviral treatments.
No takes yet. Share an insight, caveat, or question.
Aleshcheva et al. (2025) conducted an observational in Unexplained heart failure (n=75). Transcriptionally active erythroparvovirus infection vs. Patients without active erythroparvovirus infection (DCMi, DCM, and undiagnosed controls) was evaluated on Upregulation of specific miRNAs (miR-98, miR-222, miR-106b, and miR-197) (p=<0.005). Transcriptionally active erythroparvovirus infection in heart failure patients was associated with significant upregulation of miR-98, miR-222, miR-106b, and miR-197 (P<0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: